Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $42.75.

Several equities research analysts have commented on KLRA shares. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target on the stock. Jefferies Financial Group started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 target price for the company. TD Cowen assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price for the company. Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th.

Insider Transactions at Kailera Therapeutics

In other Kailera Therapeutics news, Director Andrew T. Kaplan purchased 8,398,438 shares of the company’s stock in a transaction on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the transaction, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. This represents a 47.03% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Adam Koppel bought 1,562,500 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director directly owned 22,583,268 shares of the company’s stock, valued at $361,332,288. This trade represents a 7.43% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders bought 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Stock Performance

Kailera Therapeutics stock opened at $19.37 on Friday. Kailera Therapeutics has a 12-month low of $18.85 and a 12-month high of $28.23.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.